Gonazon

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

azagly-nafarelin

Disponible depuis:

Intervet International BV

Code ATC:

QH01CA

DCI (Dénomination commune internationale):

azagly-nafarelin

Groupe thérapeutique:

Dogs; Salmonidae (Salmonid fish)

Domaine thérapeutique:

Pituitary and hypothalamic hormones and analogues

indications thérapeutiques:

Female salmonid fish such as Atlantic salmon (Salmo salar), rainbow trout (Oncorhynchus mykiss), brown trout (Salmo trutta) and Arctic charr (Salvelinus alpinus)Induction and synchronisation of ovulation for the production of eyed-eggs and fry.Dogs (bitches)Prevention of gonadal function in bitches via long term blockade of gonadotrophin synthesis.

Descriptif du produit:

Revision: 7

Statut de autorisation:

Withdrawn

Date de l'autorisation:

2003-07-20

Notice patient

                                29/37
B. PACKAGE LEAFLET
Medicinal product no longer authorised
30/37
PACKAGE LEAFLET
GONAZON CONCENTRATE FOR SOLUTION FOR INJECTION OF FEMALE SALMONID FISH
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Gonazon concentrate for solution for injection of female salmonid fish
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Azagly-nafarelin 1600

g/ml as azagly-nafarelin acetate.
Excipient: Benzyl alcohol
4.
INDICATION(S)
Induction and synchronisation of ovulation for the production of
eyed-eggs and fry.
5.
CONTRAINDICATIONS
Do not use Gonazon before approximately 10% of the specific broodstock
population has ovulated
naturally.
The product should not be used in fish maintained in water
temperatures that would normally inhibit
ovulation as this can result in a decrease in egg quality.
6.
ADVERSE REACTIONS
If you notice any serious effects or other effects not mentioned in
this leaflet, please inform your
veterinary surgeon.
7.
TARGET SPECIES
Female salmonid fish such as Atlantic salmon (_Salmo salar_), rainbow
trout (_Oncorhynchus mykiss_),
brown trout (_Salmo trutta_) and Arctic charr (_Salvelinus alpinus_).
Medicinal product no longer authorised
31/37
8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
9.
ADVICE ON CORRECT ADMINISTRATION
Inject intraperitoneally along the central line, 1/2 to 1 fin length
in front of the pelvic fin base. Fish
should be anaesthetised.
The dose should be administered in the preferred volume for the
particular body weight of fish. The
supplied solvent is used to dilute the concentrate to the correct
dilution to allow for optimisation of
the preferred injection volumes for fish of widely varying body
weights.
The empty, sterile vial is intended to be used for mixing the
concentrate 
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1/37
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2/37
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Gonazon concentrate for solution for injection of female salmonid fish
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
V
IAL CONTAINING
C
ONCENTRATE
:
ACTIVE SUBSTANCE(S)
Azagly-nafarelin 1600

g/ml as azagly-nafarelin acetate.
EXCIPIENTS
Benzyl alcohol (1%)
V
IAL CONTAINING
S
OLVENT
:
EXCIPIENTS
Benzyl alcohol (1%)
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate for solution for injection
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Female salmonid fish such as Atlantic salmon (_Salmo salar_), rainbow
trout (_Oncorhynchus mykiss_),
brown trout (_Salmo trutta_) and Arctic charr (_Salvelinus alpinus_).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Induction and synchronisation of ovulation for the production of
eyed-eggs and fry.
4.3
CONTRAINDICATIONS
Do not use Gonazon before approximately 10% of the specific broodstock
population has ovulated
naturally.
The product should not be used in fish maintained in water
temperatures that would normally inhibit
ovulation as this can result in a decrease in egg quality.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Reductions in fecundity, egg quality and survival to the eyed-egg
stage have been observed in fish
treated with azagly-nafarelin. In some cases this can be related to
the use of the compound too early in
the spawning season.
Medicinal product no longer authorised
3/37
It is recommended to strip fish after injection at intervals of
approximately 50-100 degree days.
For Arctic charr, injections should be given only if the water
temperature is < 8°C.
The long term effects of azagly-nafarelin on treated broodstock fish
have not been studied.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
High
standards
of
biosecurity
must
be
observed
at
the
time
of
injection
in
order
to
prevent
introduction and spread of infectious diseases between broodstock
fish.
SPECIAL PRECAUTIONS 
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation bulgare 15-08-2012
Notice patient Notice patient espagnol 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation espagnol 15-08-2012
Notice patient Notice patient tchèque 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation tchèque 15-08-2012
Notice patient Notice patient danois 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation danois 15-08-2012
Notice patient Notice patient allemand 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation allemand 15-08-2012
Notice patient Notice patient estonien 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation estonien 15-08-2012
Notice patient Notice patient grec 15-08-2012
Notice patient Notice patient français 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation français 15-08-2012
Notice patient Notice patient italien 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation italien 15-08-2012
Notice patient Notice patient letton 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation letton 15-08-2012
Notice patient Notice patient lituanien 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation lituanien 15-08-2012
Notice patient Notice patient hongrois 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation hongrois 15-08-2012
Notice patient Notice patient maltais 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation maltais 15-08-2012
Notice patient Notice patient néerlandais 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation néerlandais 15-08-2012
Notice patient Notice patient polonais 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation polonais 15-08-2012
Notice patient Notice patient portugais 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation portugais 15-08-2012
Notice patient Notice patient roumain 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation roumain 15-08-2012
Notice patient Notice patient slovaque 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation slovaque 15-08-2012
Notice patient Notice patient slovène 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation slovène 15-08-2012
Notice patient Notice patient finnois 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation finnois 15-08-2012
Notice patient Notice patient suédois 15-08-2012
Rapport public d'évaluation Rapport public d'évaluation suédois 15-08-2012
Notice patient Notice patient norvégien 15-08-2012
Notice patient Notice patient islandais 15-08-2012

Rechercher des alertes liées à ce produit

Afficher l'historique des documents